Paul Tudor Jones Arcutis Biotherapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 20,964 shares of ARQT stock, worth $314,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,964Holding current value
$314,250% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$175 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$164 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$161 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$132 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$129 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $902M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...